Innate Pharma SA

IPHA · NYSE

$1.50+$0.00 (+0.00%)TodayMarket closed · Oct 23, 6:48 PM ET

Prev close $1.50

Latest news

Press releaseOct 21, 1:00 AM ETBusiness Wire
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
Press releaseOct 20, 1:00 AM ETBusiness Wire
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
NewsSep 17, 8:27 AM ET
Innate Pharma H1 2026 Earnings Call Transcript
NewsSep 17, 7:11 AM ET
Earnings Scheduled For September 17, 2026
Press releaseSep 17, 1:00 AM ETBusiness Wire
Innate Pharma Reports First Half 2026 Business Update and Financial Results
Press releaseSep 16, 4:00 PM ETBusiness Wire
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
Press releaseSep 10, 1:00 AM ETBusiness Wire
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
Press releaseSep 2, 1:00 AM ETBusiness Wire
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NewsAug 14, 8:06 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseAug 14, 5:30 AM ETBusiness Wire
Innate Pharma Announces Conference Call and Webcast
NewsAug 12, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsAug 12, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsAug 10, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsAug 10, 10:03 AM ETVandana Singh
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
NewsAug 10, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsAug 10, 7:18 AM ET
Market-Moving News for August 10th
Press releaseAug 10, 2:32 AM ETPRNewswire
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
Press releaseAug 10, 2:30 AM ETBusiness Wire
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Press releaseAug 10, 2:00 AM ETBusiness Wire
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Press releaseJul 23, 1:00 AM ETBusiness Wire
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Press releaseJul 21, 1:00 AM ETBusiness Wire
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Press releaseJun 2, 9:02 AM ETPRNewswire
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
Press releaseMay 22, 1:00 AM ETBusiness Wire
Outcome of Innate Pharma's 2026 Annual General Meeting
Press releaseMay 19, 1:00 AM ETBusiness Wire
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Press releaseMay 18, 2:22 PM ETPRNewswire
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
NewsMay 14, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMay 14, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseMay 13, 1:00 AM ETBusiness Wire
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Press releaseMay 12, 1:00 AM ETBusiness Wire
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
Press releaseMay 6, 1:00 AM ETBusiness Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
Press releaseApr 23, 1:00 AM ETBusiness Wire
Innate Pharma to Participate in the D. Boral Capital Global Conference
NewsApr 17, 3:01 PM ET
Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026
Press releaseApr 17, 3:00 PM ETBusiness Wire
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
NewsSep 18, 10:00 AM ETAvi Kapoor
This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
NewsSep 18, 8:16 AM ETAvi Kapoor
Alphabet To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

Innate Pharma H1 2026 Earnings Call Transcript

Earnings Scheduled For September 17, 2026

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

12 Health Care Stocks Moving In Friday's Pre-Market Session

Innate Pharma Announces Conference Call and Webcast

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy

12 Health Care Stocks Moving In Monday's Pre-Market Session

Market-Moving News for August 10th

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

Outcome of Innate Pharma's 2026 Annual General Meeting

Innate Pharma to participate in the Jefferies Global Healthcare Conference

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

Innate Pharma to Participate in the D. Boral Capital Global Conference

Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Alphabet To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday